Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cell-free DNA (cfDNA) testing for fetal trisomy is highly effective among high-risk women. However, there have been few direct, well-powered studies comparing cfDNA testing with standard screening during the first trimester in routine prenatal populations. METHODS: In this prospective, multicenter, blinded study conducted at 35 international centers, we assigned pregnant women presenting for aneuploidy screening at 10 to 14 weeks of gestation to undergo both standard screening (with measurement of nuchal translucency and biochemical analytes) and cfDNA testing. Participants received the results of standard screening; the results of cfDNA testing were blinded. Determination of the birth outcome was based on diagnostic genetic testing or newborn examination. The primary outcome was the area under the receiver-operating-characteristic curve (AUC) for trisomy 21 (Down's syndrome) with cfDNA testing versus standard screening. We also evaluated cfDNA testing and standard screening to assess the risk of trisomies 18 and 13. RESULTS: Of 18,955 women who were enrolled, results from 15,841 were available for analysis. The mean maternal age was 30.7 years, and the mean gestational age at testing was 12.5 weeks. The AUC for trisomy 21 was 0.999 for cfDNA testing and 0.958 for standard screening (P=0.001). Trisomy 21 was detected in 38 of 38 women (100%; 95% confidence interval [CI], 90.7 to 100) in the cfDNA-testing group, as compared with 30 of 38 women (78.9%; 95% CI, 62.7 to 90.4) in the standard-screening group (P=0.008). False positive rates were 0.06% (95% CI, 0.03 to 0.11) in the cfDNA group and 5.4% (95% CI, 5.1 to 5.8) in the standard-screening group (P<0.001). The positive predictive value for cfDNA testing was 80.9% (95% CI, 66.7 to 90.9), as compared with 3.4% (95% CI, 2.3 to 4.8) for standard screening (P<0.001). CONCLUSIONS: In this large, routine prenatal-screening population, cfDNA testing for trisomy 21 had higher sensitivity, a lower false positive rate, and higher positive predictive value than did standard screening with the measurement of nuchal translucency and biochemical analytes. (Funded by Ariosa Diagnostics and Perinatal Quality Foundation; NEXT ClinicalTrials.gov number, NCT01511458.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, cfDNA analysis has been useful for non-invasive prenatal testing applications, such as for the identification of trisomy 21 (ref.124).”
From Clinical metagenomics (2019) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., Berkowitz, R. L., Gross, S. J., Dugoff, L., Craigo, S. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043693 · Cited by 1,081
Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., van den Boom, D., Bombard, A. T., Deciu, C., Grody, W. W., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182368a0e · Cited by 939
Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14791 · Cited by 807
Akolekar, R., Beta, J., Picciarelli, G., Ogilvie, C., & D'Antonio, F. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14636 · Cited by 711
Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population
Nicolaides, K. H., Syngelaki, A., Ashoor, G., Birdir, C., & Touzet, G. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.08.033 · Cited by 624
DNA Sequencing versus Standard Prenatal Aneuploidy Screening
Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F., Craig, J. A., Chudova, D. I., Devers, P. L., Jones, K. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311037 · Cited by 620
Norton, M. E., Brar, H., Weiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., Rodriguez, M. H., Williams, J., Mitchell, M. E., Adair, C. D., et al. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.05.021 · Cited by 596
Self-citationFirst-Trimester Screening for Trisomies 21 and 18
Wapner, R., Thom, E., Simpson, J. L., Pergament, E., Silver, R., Filkins, K., Platt, L., Mahoney, M., Johnson, A., Hogge, W. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025273 · Cited by 563
Self-citationDNA Sequencing Versus Standard Prenatal Aneuploidy Screening
Rochon, M. L. (2014) · Cited by 468
Cited by
Items 801–817 of 817
Al-Hajaya, Y. (2026) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3454
Hsu, C., Liu, Q., & Shyr, Y. (2026) · medRxiv · doi:10.64898/2026.07.15.26358166
An, P., Zhu, J., Zhao, Y., Zhou, J., Song, M., Chen, Y., Chen, S. J., Cj, X., Lei, C., Zhou, J., et al. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.71252
Interpreting False-Positive or Atypical Prenatal Cell-Free DNA Results
Tinkle, M. B., & Reese, A. (2026) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1016/j.jogn.2026.06.003
Tuvshinjargal, K., Batbayar, G., Oyunbat, N., Damdinbazar, D., Purevsuren, J., Tsendsuren, O., & Davaakhuu, G. (2026) · Reproductive Medicine · doi:10.3390/reprodmed7030037
Zhang, Z., Wang, S., Jiang, J., Sheng, J., Zhang, B., Li, Z., & Wang, Z. (2026) · Journal of medicine and physical education. · doi:10.62517/jmpe.202618308
Bashir, I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27660-6.00010-9
Srinivasan, V., & Rather, R. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27660-6.00011-0
Duquenne, A., Brison, N., Parijs, I., Pagliazzi, A., Baetens, M., Blaumeiser, B., Bruneau, M., Bulk, S., Callewaert, B., Coppens, S., et al. (2026) · Prenatal Diagnosis · doi:10.1002/pd.70236
Doi, K., Yamaguchi, M., Iwai, M., Terakawa, C., Makino, S., Maruyama, R., Kusumoto, K., Sato, K., Tomimori, K., Goto, Y., et al. (2026) · Journal of Genetic Counseling · doi:10.1002/jgc4.70286
Northrop, L. E., Eastway, J., Ravuri, S., & Fairbrother, G. L. (2026) · Diagnostics · doi:10.3390/diagnostics16182936
Prenatal cytogenetic screening in the genomic era: an updated evidence review
Bhatiya, A. R., Oza, A. D., Gandhi, N. V., & Thakor, J. (2026) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2026.101339
Muresan, M. C., Muresan, M. B., Dumitrascu-Biris, D., & Popescu, D.-E. (2026) · Life · doi:10.3390/life16101677
Al‐Hajaya, Y. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00630
Ahmadi, S., Dafrazi, F. M., & Homayuni, M. R. A. (2026) · Journal of Ultrasound · doi:10.1007/s40477-026-01249-2
Liquid Biopsy: Past, Present, and Future
Liu, J., Zeng, D., Zhao, K., Wang, Y., Hu, H., Deng, F., Wang, Y., Sun, L., & Fu, L. (2026) · MedComm · doi:10.1002/mco2.71085
Non-invasive Prenatal Screening for Fetal Aneuploidy: Comparison with Cytogenetic Results
Meck, J. M., Putcha, G. V., & Cherry, A. M. (2015) · Current Genetic Medicine Reports · doi:10.1007/s40142-015-0072-z
Metadata
- Authors
- Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., Cuckle, H., Musci, T. J., & Wapner, R. J.
- Affiliations
- Saint Peter's University Hospital (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of California San Diego (US)
- Oregon Health & Science University (US)
- Perinatal Quality Foundation (US)
- Columbia University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-23
- Volume
- 372
- Issue
- 17
- Pages
- 1589-1597
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139926668
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 33 · 2025: 39 · 2024: 50 · 2023: 59 · 2022: 61 · 2021: 86 · 2020: 72 · 2019: 74 · 2018: 73 · 2017: 86 · 2016: 107 · 2015: 75
- FWCI
- 113.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Västra Götalandsregionen
- Thomas Jefferson University
- University of California, San Diego
- University of California, San Francisco
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Health Sciences › Medicine › Obstetrics and Gynecology › Maternal and Perinatal Health Interventions
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Assisted Reproductive Technology and Twin Pregnancy
- Keywords
- cell-free DNA, prenatal aneuploidy screening, Down syndrome, trisomy 18, trisomy 13, first-trimester screening, nuchal translucency, biochemical analytes, diagnostic accuracy, false positive rate, positive predictive value, non-invasive prenatal testing, maternal age
- MeSH terms
- Adolescent, Adult, Chromosome Aberrations, DNA, Down Syndrome, False Positive Reactions, Female, Fetus, Humans, Middle Aged, Pregnancy, Pregnancy Trimester, First, Prenatal Diagnosis, Prospective Studies, Sensitivity and Specificity, Single-Blind Method, Area Under Curve, Nuchal Translucency Measurement, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.